'Have to ensure sustainability': Serum on pricing Covishield at Rs 600/dose

Serum, which produces the Oxford-AstraZeneca vaccine locally said that initial prices were kept very low globally as it was based on advance funding given by some countries

Serum Institute of India cleared the air on concerns expressed over the supposedly high market price for its Covishield vaccine, saying the comparison being done between global prices of the coronavirus vaccine with India is inaccurate.

Serum, which produces the Oxford-AstraZeneca vaccine at its Pune facility, said that initial prices were kept very low globally as it was based on advance funding given by some countries for vaccine manufacturing.

"The initial supply price of Covishield for all government immunisation programme, inculding India has been the lowest," the company has said on Saturday.

Serum said it would price its vaccine Covishield at Rs 400